ECSP088758A - Métodos para reducir la aglomeración de proteína - Google Patents

Métodos para reducir la aglomeración de proteína

Info

Publication number
ECSP088758A
ECSP088758A EC2008008758A ECSP088758A ECSP088758A EC SP088758 A ECSP088758 A EC SP088758A EC 2008008758 A EC2008008758 A EC 2008008758A EC SP088758 A ECSP088758 A EC SP088758A EC SP088758 A ECSP088758 A EC SP088758A
Authority
EC
Ecuador
Prior art keywords
methods
protein
aglomeration
reduce protein
formulations
Prior art date
Application number
EC2008008758A
Other languages
English (en)
Inventor
Li Li
Angela Kantor
Nicholas W Warne
Thomas Crowley
Nicholas Luksha
Erin Soley
Edie Anna Neidhardt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088758A publication Critical patent/ECSP088758A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para reducir la aglomeración de una proteína o proteínas en una formulación y formulaciones de proteínas que tienen propiedades de aglomeración reducidas. Los métodos y formulaciones descritas en este documento, mantienen la actividad biológica de una proteína e incrementan la vida de anaquel de las formulaciones de proteína.
EC2008008758A 2006-03-20 2008-09-22 Métodos para reducir la aglomeración de proteína ECSP088758A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78413006P 2006-03-20 2006-03-20

Publications (1)

Publication Number Publication Date
ECSP088758A true ECSP088758A (es) 2008-10-31

Family

ID=38523027

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008758A ECSP088758A (es) 2006-03-20 2008-09-22 Métodos para reducir la aglomeración de proteína

Country Status (18)

Country Link
US (1) US20080064856A1 (es)
EP (1) EP1996221A2 (es)
JP (1) JP2009530380A (es)
KR (1) KR20080108554A (es)
CN (1) CN101420972A (es)
AR (1) AR059964A1 (es)
AU (1) AU2007227408A1 (es)
BR (1) BRPI0709059A2 (es)
CA (1) CA2646934C (es)
CR (1) CR10290A (es)
EC (1) ECSP088758A (es)
IL (1) IL194123A0 (es)
MX (1) MX2008011888A (es)
NO (1) NO20083940L (es)
PE (1) PE20080121A1 (es)
RU (1) RU2008137634A (es)
TW (1) TW200806317A (es)
WO (1) WO2007109221A2 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2007003936A1 (en) * 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
US20100297081A1 (en) * 2007-12-18 2010-11-25 Huang Yanshan Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
BRPI0915414A2 (pt) 2008-06-20 2021-09-08 Novartis Ag Métodos para identificar uma região propensa à agregação e uma região de ligação de macromolécula em uma proteína, bem como métodos para produzir uma variante de proteína e uma composição farmacêutica.
MX2010014079A (es) * 2008-06-20 2011-02-22 Novartis Ag Inmunoglobulinas con agregacion reducida.
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2010031720A2 (en) * 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
KR20180056805A (ko) 2009-06-04 2018-05-29 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
MY159865A (en) * 2009-07-06 2017-02-15 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
CA2782444C (en) 2010-02-04 2018-10-23 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
MX341918B (es) 2011-01-04 2016-09-07 Archivel Farma Sl Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
RS56429B1 (sr) * 2011-05-02 2018-01-31 Millennium Pharm Inc Formulacija za anti- 4 7 antitelo
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112014010186A2 (pt) 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
EP2802345B1 (en) 2012-01-12 2018-03-07 Archivel Farma, S.l. Mtb-c vaccine against allergic responses
EP2838552A4 (en) 2012-04-19 2016-05-18 Opko Biolog Ltd OXYNTOMODULIN VARIANTS WITH EXTENDED ACTION AND PROCESSES FOR PRODUCING SAME
US10132736B2 (en) * 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
JP6129832B2 (ja) * 2012-05-29 2017-05-17 日本ハム株式会社 食品成分抽出液および抽出方法
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
SG10201610223PA (en) 2012-11-20 2017-02-27 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP4242321A3 (en) 2013-08-05 2023-09-27 Twist Bioscience Corporation De novo synthesized gene libraries
US20150126444A1 (en) * 2013-10-21 2015-05-07 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3114138B1 (en) * 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
KR102192494B1 (ko) 2014-08-04 2020-12-18 시에스엘 리미티드 인자 viii 제형
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
HUE066258T2 (hu) * 2015-07-30 2024-07-28 Biomarin Pharm Inc A C-típusú natriuretikus peptid variánsok alkalmazása a csontrendszeri diszplázia kezelésére
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation BANKS OF OLIGONUCLEIC ACID VARIANTS AND SYNTHESIS THEREOF
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
PT3481855T (pt) 2016-07-11 2023-11-27 Opko Biologics Ltd Fator vii de coagulação de ação prolongada e métodos de produção do mesmo
EP3500672A4 (en) 2016-08-22 2020-05-20 Twist Bioscience Corporation NOVO SYNTHESIZED NUCLEIC ACID BANKS
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
EP3586255A4 (en) 2017-02-22 2021-03-31 Twist Bioscience Corporation NUCLEIC ACID-BASED DATA STORAGE
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CA3056388A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
EP3681906A4 (en) 2017-09-11 2021-06-09 Twist Bioscience Corporation GPCR-BINDING PROTEINS AND THEIR SYNTHESIS
KR20240024357A (ko) 2017-10-20 2024-02-23 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
JP7158015B2 (ja) 2017-11-09 2022-10-21 国立研究開発法人産業技術総合研究所 ポリペプチドの凝集化抑制方法
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN112639130B (zh) 2018-05-18 2024-08-09 特韦斯特生物科学公司 用于核酸杂交的多核苷酸、试剂和方法
WO2020044204A1 (en) * 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
US11492727B2 (en) * 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
US20220227824A1 (en) * 2019-06-24 2022-07-21 The Children's Hospital Of Philadelphia Use of srrd in the inhibition of protein aggregation
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
KR20220033504A (ko) * 2019-07-11 2022-03-16 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 흉선 기질 림프포이에틴(tslp)-수용체 신호전달을 방해하는 제제
JP2023538669A (ja) * 2020-08-24 2023-09-08 アムジェン インコーポレイテッド Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU741300B2 (en) * 1997-09-23 2001-11-29 Rentschler Biotechnologie Gmbh Liquid interferon-beta formulations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
HUP0301349A3 (en) * 1999-07-15 2005-12-28 Genetics Inst Llc Cambridge Formulations for il-11
HU227347B1 (en) * 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
ATE355849T1 (de) * 2000-12-21 2007-03-15 Nektar Therapeutics Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7051050B2 (en) * 2002-03-19 2006-05-23 Netwrok Appliance, Inc. System and method for restoring a single file from a snapshot
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
PT1517698E (pt) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
ES2321297T3 (es) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
ATE554792T1 (de) * 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
AU2005249233B2 (en) * 2004-06-01 2010-10-07 Ares Trading S.A. Stabilized interferon liquid formulations
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations

Also Published As

Publication number Publication date
MX2008011888A (es) 2008-09-29
RU2008137634A (ru) 2010-04-27
CN101420972A (zh) 2009-04-29
CA2646934A1 (en) 2007-09-27
IL194123A0 (en) 2011-08-01
CA2646934C (en) 2014-09-23
AR059964A1 (es) 2008-05-14
BRPI0709059A2 (pt) 2011-06-21
US20080064856A1 (en) 2008-03-13
TW200806317A (en) 2008-02-01
JP2009530380A (ja) 2009-08-27
WO2007109221A3 (en) 2008-02-21
CR10290A (es) 2008-11-26
KR20080108554A (ko) 2008-12-15
EP1996221A2 (en) 2008-12-03
WO2007109221A9 (en) 2007-12-06
WO2007109221A2 (en) 2007-09-27
AU2007227408A1 (en) 2007-09-27
NO20083940L (no) 2008-10-16
PE20080121A1 (es) 2008-03-05

Similar Documents

Publication Publication Date Title
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
CR20170130A (es) Formulaciones de pepticuerpos terapéuticos liofilizados
CR10889A (es) Antagonistas de activina-actrii y sus usos para incrementar los niveles de globulos rojos en la sangre
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
UY29196A1 (es) Composiciones de aceites de semillas
BRPI0514340A (pt) formulações de estabilização
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
MX354100B (es) Formulaciones de proteinas y metodos para elaborarlas.
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
ECSP099678A (es) Composiciones de carne de pescados y mariscos que comprenden productos de proteina estructurada
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
BRPI0606687A2 (pt) composições nutracêuticas
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
CY1112992T1 (el) Μεσο καλλιεργειας χωρις ορο για την παρασκευη ανασυνδυασμενων γοναδοτροπινων
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
HN2008001793A (es) Enzima mdo modificada y metodo para su utilizacion